A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Recruiting

Phase 2

IO102/IO103, Nivolumab, RelatlimabA Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05912244

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IO102/IO103

Nivolumab-Relatlimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-04. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-08-14.